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Abstract
Therapeutic strategies in dystonia have evolved considerably in the past few decades. Three major treatment
modalities include oral medications, botulinum toxin injections and surgical therapies, particularly deep brain
stimulation. Although there has been a tremendous interest in the later two modalities, there are relatively few
recent reviews of oral treatment. We review the medical treatment of dystonia, focusing on three major
neurotransmitter systems: cholinergic, GABAergic and dopaminergic. We also provide a practical guide to
medication selection, therapeutic strategy and unmet needs.
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Introduction
Three main approaches are employed in the treatment
of dystonia: pharmacological therapies, botulinum toxin
injection (BoNT) and surgical interventions. The current
review focuses only on medical therapy, as this area is
less commonly addressed in the literature. Four major
categories of medications are most commonly used:
anticholinergics (particularly trihexyphenidyl), baclofen, ben-
zodiazepines (particularly clonazepam), and dopamine-
related medications. We suggest the mnemonic “ABCD”,
which stands for Anticholinergics or Artane®, Baclofen,
Clonazepam, and Dopamine-related medications as a
helpful way to remember these options. Medical therapy in
dystonia is largely empiric, and at times may seem
anecdotal.
Review
Neurotransmitter systems critical to medical treatment in
dystonia
Three main neurotransmitter systems are involved: cho-
linergic, GABAergic and dopaminergic systems. We will
consider each system separately (Fig. 1).
Cholinergic system
Giant aspiny interneurons or cholinergic interneurons
(ChIs) serve as an intrinsic source of acetylcholine
(ACh) to the medium spiny neurons (MSNs) in the
striatum, whereas pedunculopontine nucleus neurons
serve as an extrinsic source. ChIs comprise only 1–3% of
all striatal cells, but provide a main source of ACh to the
MSNs. They are also referred to as tonically active neu-
rons, given characteristic property of autonomous firing
without synaptic activity [1]. Hyperactivity of the ChIs
may explain improvement of dystonia with anticholiner-
gics [2]. More recent evidence has also supported the
role of ChIs in abnormal corticostriatal synaptic plasti-
city [3].
Several anticholinergics including trihexyphenidyl,
benztropine, ethopropazine, procyclidine and biperiden
have been used in dystonia [4–8]. Trihexyphenidyl is the
most commonly employed medication. Benztropine is
less frequently used, whereas the others are infrequently
used in current clinical practice. Generally the anticholin-
ergics act as antagonists at postsynaptic M1 receptors. Some
medications also act at other receptors, e.g. biperiden at nic-
otinic receptors, and procyclidine at M2 and M4 receptors.
GABAergic system
GABA is an inhibitory neurotransmitter in the brain and
spinal cord. In addition to the MSNs, GABA is present
widely in neurons subserving basal ganglia circuitry. The
role of GABA in dystonia pathophysiology remains un-
clear. One study showed abnormal GABAA receptor
binding in motor cortices in primary dystonia, probably
leading to sensorimotor disinhibition [9]; another study
found no change in focal hand dystonia [10].
As a muscle relaxant, baclofen is an agonist of GABAB re-
ceptors at presynaptic terminals of excitatory glutamatergic
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neurons, and at postsynaptic sites of inhibitory interneurons
in the spinal cord [11]. Its mechanism in dystonia is less
understood. Baclofen is generally considered to be less
effective than anticholinergics for dystonia [6].
Benzodiazepines are also medications primarily
affecting the GABAergic system. They increase the
frequency of chloride channel opening after binding
to GABAA receptors, which eventually facilitates in-
hibitory signals. Zolpidem increases chloride influx
after binding to BZ1 receptors near, but not at the
GABAA binding site of benzodiazepines in GABAA
receptor complexes.
Dopaminergic system
Medications primarily affecting the dopaminergic system
can be divided into 1) levodopa and 2) dopamine reducing
medications including presynaptic dopamine depletors
(such as tetrabenazine [TBZ]) and postsynaptic dopamine
blocking agents (DRBAs such as clozapine, quetiapine,
and typical neuroleptics). The mechanism of action of
levodopa in dystonia other than dopa-responsive dystonia
(DRD) remains poorly understood. It appears counterintu-
itive that both levodopa and dopamine-reducing strategies
provide benefit in dystonia.
TBZ inhibits the enzyme vesicular monoamine trans-
porter 2 (VMAT2), thereby reducing transport of dopamine
into presynaptic vesicles. Reserpine also inhibits VMAT2,
but it has peripheral effects as well. Metyrosine (a.k.a.
α-methyl-para-tyrosine or Demser®) inhibits tyrosine
hydroxylase, a presynaptic enzyme required for dopa-
mine synthesis.
DRBAs act by blocking dopamine receptors at postsyn-
aptic sites. Typical neuroleptics generally have effects at
D2 receptors, whereas atypical neuroleptics (e.g. clozapine
and quetiapine) possess less risk of triggering acute
dystonic reaction or tardive syndromes.
The evaluation and initiation of medical treatment in
dystonia
We present a practical approach for initiating medical
treatment in a patient with dystonia (Table 1). We
organize the discussion around four central questions.
1) Does the patient really have dystonia?
This is the first and most important question to
answer before initiating treatment. Clinicians must be
able to differentiate pseudodystonia and psychogenic
dystonia from true dystonia. Useful clues for
psychogenicity include rapid onset, fixed postures
which do not vary over time, inconsistency and
variability on exam. Some important examples of
pseudodystonia include congenital torticollis (where
surgical release of the fibrotic muscular tissue may be
indicated), atlantoaxial subluxation (requiring urgent
orthopedic management), and stiff limb syndrome
(which requires immunotherapy).
(See figure on previous page.)
Fig. 1 The three major neurotransmitters in dystonia. This figure illustrates the three neurotransmitters in the striatum (cholinergic [in pink], GABAergic
[in yellow and brown] and dopaminergic [in blue]), their processes at synaptic levels and affected targets. Of note, other neurotransmitters such as
cannabinoids and serotonin may also play a role in dystonia but are not shown here. 1) Cholinergic system. Giant asypiny or cholinergic
interneurons (ChIs; in pink), also referred to as tonically active neurons (TANs), are a main cholinergic input to medium spiny neurons (MSNs; in yellow)
in the striatum. At the synaptic level, ACh is synthesized in presynaptic terminals by acetylation of choline, catalyzed by the enzyme choline
acetyltransferase (ChAT). ACh is then transported into vesicles by the vesicular ACh transporter (VAChT). After ACh is released at synaptic clefts, it binds
to muscarinic (M1-4 subtypes) and/or nicotinic receptors in order to have further action downstream. The remaining ACh at the synaptic cleft is
subsequently metabolized by acetylcholinesterase (AChE) into acetate and choline. The latter is taken up into the presynaptic terminal by the choline
transporter (CHT). 2) GABAergic system. GABA is present widely in neurons subserving basal ganglia circuitry including the MSNs, and both internal
and external segments of the globus pallidus. In this figure, only the synapse between the MSN and the pallidal cell (in brown) is demonstrated. At the
synaptic level, GABA is synthesized from glutamate in presynaptic terminals. It is then packed into vesicles via the vesicular GABA transporter (VGAT)
before being released into synaptic clefts. GABA subsequently binds to postsynaptic receptors. The remaining GABA at the synaptic clefts is
transported back to presynaptic terminals by two methods: 1) direct reuptake by GABA transporters (GAT) at presynaptic terminals 2) indirect transport
via adjacent glial cells requiring transformation to glutamine prior to returning to presynaptic terminals. 3) Dopaminergic system. The MSNs also
receive dopaminergic input from neurons in the substantia nigra pars compacta (SNc) via the nigrostriatal pathway (in blue). At the synaptic level,
dopamine is synthesized in presynaptic terminals from tyrosine by the enzyme tyrosine hydroxylase (TH) requiring tetrahydrobiopterin (BH4) as a
cofactor. Dopamine (DA) and other monoamines are packaged into vesicles in presynaptic terminals by the enzyme vesicular monoamine transporter
2 (VMAT2). The monoamines are then released to synaptic clefts and bind to postsynaptic receptors including dopamine receptors (D1-5). Dopamine at
synaptic clefts is degraded by the enzymes monoamine oxidase (MAO) and cathechol-O-methyl transferase (COMT) into 3,4-dihydroxyphenylacetic acid
(DOPAC) and 3-methoxytyramine (3-MT) respectively. The remaining dopamine is subsequently transported back to presynaptic terminals by the dopamine
transporters (DAT). The prototypic medications affecting each neurotransmitter systems and their sites of action are listed at the left lower corner.
Anticholinergics act postsynaptically as muscarinic receptor antagonists, particularly at M1 receptors. Baclofen is a GABAB receptor agonist. In the spinal
cord, it acts at both presynaptic (excitatory glutamatergic neurons) and postsynaptic (of inhibitory interneurons) terminals. However, its sites of action in the
basal ganglia (presynaptic vs. postsynaptic or both) remain unclear (shown as “?”). Benzodiazepines (BZDs) bind to GABAA receptors, leading to increased
frequency of chloride channel opening and thereby inhibitory signals. Levodopa (L-DOPA) is converted to dopamine in presynaptic terminals by the enzyme
DOPA decarboxylase (DDC). Dopamine depleting agents such as tetrabenazine (TBZ) acts at presynaptic terminals by inhibiting the VMAT2 enzyme which then
impairs dopamine transport into vesicles. Dopamine receptor blocking agents (DRBAs), in contrast, acts postsynaptically by blocking dopamine receptors
Termsarasab et al. Journal of Clinical Movement Disorders  (2016) 3:19 Page 3 of 18
2) Is there an etiology-specific treatment for the
patient?
This is the next step once the diagnosis of true
dystonia is secured. Treatment in dystonia can be
classified as etiology-based vs. symptomatic. While
most treatments remain symptom-based, etiology-
based treatments exist for a few forms of dystonia
(“don’t-miss” diagnoses”) and can provide remarkable
benefits. They can be grouped into three main cate-
gories: neurometabolic disorders, heavy metal-related
disorders, and acquired dystonia (Table 2).
The quintessential “don’t-miss” diagnosis is DRD
in which levodopa serves as an etiology-specific
therapy. DRDs typically have dramatic and sustained
response to levodopa [12], and their phenotypes are
broad [13, 14]. DRD can present with focal, segmen-
tal or generalized dystonia in children, or with limb-
onset focal or segmental dystonia in adults [13, 14].
The first responsible gene was discovered in 1994
when Ichinose first reported mutations in the
GCH1 gene encoding the enzyme GTP cyclohydro-
lase I [15]. This enzyme is essential in the synthesis
of tetrahydrobiopterin (BH4), a cofactor required in
the synthetic pathways of monoamines including
dopamine and serotonin. Less common genes in-
cluding TH1 (encoding tyrosine hydroxylase, the
rate limiting step in dopamine synthesis) and SPR
(encoding sepiapterin reductase, another enzyme
required for BH4 synthesis) were later discovered
[16, 17].
An observed levodopa trial (generally up to 300–
400 mg of levodopa daily in adults or 4–5 mg/kg/
day in children [18], for at least one month) is
recommended in all children with any forms of
dystonia, and adults whose phenotypes cannot
exclude DRD. However, the dose ranges may vary
depending on the genotypes e.g. as shown in one
study, 100–400 mg/day in adult patients with GCH1
mutations vs. 150–600 mg/day in adult non-GCH1
patients [19]. Children with autosomal recessive forms
of DRD such as autosomal-recessive GCH1, TH and
SPRmutations may require higher dose (e.g. 6–10 mg/
kg/day), as opposed to conventional dose, 4–5 mg/kg/
day, in autosomal dominant GCH1mutations [14, 18].
Exposing patients to high doses (e.g. up to
1000 mg/day in adults or 16–20 mg/kg/day in
children) [12, 14] is not usually recommended
prior to genetic confirmation [18].
DRD patients typically have an excellent and
sustained response to levodopa [12, 20]. In the long
term, patients usually stay on relatively low and
stable (or even lower) doses in adulthood [12, 21].
Wearing off phenomenon and levodopa-induced dys-
kinesias are much less common than in Parkinson’s
disease, but have been reported [12, 20, 22–24], par-
ticularly in autosomal recessive forms (e.g. TH,
SPR mutations) as opposed to autosomal domin-
ant DRD [14]. Levodopa-induced dyskinesias also
tend to occur at higher doses, and are improved
by dose reduction without worsening of motor
Table 1 Practical guide for initiation of medications and
selection of symptomatic medical therapies
A. Questions to ask before initiating treatment:
1) “Does the patient really have dystonia?”
- Exclude pseudodystonia and psychogenic dystonia
2) “Is there any (etiology-) specific treatment for the patient?”
- Identify treatable dystonia (Table 2): neurometabolic disorders
(DRD being the most important), heavy metal-related disorders
(especially Wilson’s disease) and acquired disorders
3) Is there any coexisting phenomenology other than dystonia?
- Identify and appropriately treat coexisting phenomenology
such as parkinsonism (e.g. in RDP) or myoclonus (e.g. in
myoclonus-dystonia syndrome or DYT11 dystonia)
4) “What treatment modality or modalities should be initiated?”
- Selecting between medications vs. BoNT vs. DBS
or combination (Table 3)
B. General principles of symptomatic medical treatment in dystonia
• Trihexyphenidyl is a first-line agent
• Baclofen and clonazepam are typically second-line agent
• TBZ or clozapine may be considered as first-line agents
in tardive dystonia
• Start low, go slow
o Initiate at a low dose
o Titrate up slowly
▪ Every 3–4 days in children and younger adults
▪ Every 1 week for older adults or patients prone
to side effects
• Continue uptitration if non-sustained benefits or inadequate
symptom control
• If side effects occur – may initially try holding the dose
constant. If no improvement, or severe/intolerable side effects
– lower the dose (modified from Ref [5])
o If side effects disappear and patient still benefits:
▪ Consider combination therapy or try increasing the
dose slowly again
o If side effects disappear but no benefit:
▪ Consider discontinuation (may need slow tapering
especially baclofen and clonazepam)
o If side effects persist but patient still benefits:
▪ Consider lowering the dose further
o If side effects persist and no benefit
▪ Consider discontinuation (or slow tapering)
o If benefits are seen and symptoms are adequately
controlled:
▪ Hold constant to see if benefits are sustained.
• Of note, sometimes trihexyphenidyl at a constant dose
may require 2–4 weeks to reach peak benefit
• Trihexyphenidyl may have paradoxical effects at low doses
o If this occurs – may try pushing to higher doses slowly
A. Step-by-step approach before initiation of medical treatment in dystonia:
a practical guide
B. General principles of symptomatic medical treatment in dystonia. Further
detail is described in the review
Abbreviations: BoNT, botulinum toxin injection, DBS deep brain stimulation,
DRD dopa-responsive dystonia, RDP rapid-onset dystonia parkinsonism,
TBZ tetrabenazine
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functions. Additional therapies may be required in
some forms of DRD such as 5-hydroxytryptophan
(5-HTP, up to 6 mg/kg/day) in sepiapterin reductase
deficiency [25, 26], and 5-HTP and BH4 in autosomal
recessive GCH1 mutations [27].
Among heavy metal-related disorders, Wilson’s
disease is the prototypical “don’t-miss” diagnosis.
Treatment includes chelation therapies (D-peni-
cillamine, trientine and tetrathiomolybdate) and
zinc sulfate [28–31]. Among treatable neurome-
tabolic disorders, cerebrotendinous xanthomatosis
deserves special mention, and careful search for
tendon xanthoma and blood levels of cholestanol are
useful prior to genetic testing. It is treatable with
chenodeoxycholic acid.
Niemann-Pick type C can present with dystonia,
in addition to ataxia and vertical supranuclear gaze
palsy [32–34]. Treatment with miglustat (N-butyl-
deoxynojirimycin) has been shown to improve or
stabilize neurological manifestations [35, 36].
Neurodegeneration with brain iron accumulation
(NBIA), another example of heavy metal-related
disorders, has been reported to benefit from iron
chelation with deferiprone [37, 38], although this
needs further study.
Even when an etiology-specific approach is avail-
able, symptomatic medical therapies can still be
employed as an adjunct or bridging therapy until the
specific treatment achieves maximal benefit. For ex-
ample, in Wilson’s disease, anticholinergics can be
Table 2 Dystonic disorders where etiology-specific treatment is available
Dystonic disorders where etiology-specific treatment is available
The disorders in this group can be categorized into neurometabolic disorders, heavy metal-related disorders and acquired disorders. The disorders in each
subgroup are listed. The therapies are listed on the rightmost column. In the first two groups, the middle column demonstrated underlying enzymatic or protein
defects with responsible genes in parentheses
Abbreviations: AADC aromatic amino acid decarboxylase, GLUT1 glucose transporter type 1, IVIG intravenous immunoglobulin, LGI1 leucine-rich glioma-inactivated
1, NMDA N-methyl-D-aspartate
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used to symptomatically treat dystonia concurrently
with copper chelation.
3) Is dystonia the only phenomenology? Or are there
coexisting phenomenologies other than dystonia?
“Dystonia-plus syndromes” [39, 40] or “combined
dystonia” [41] have co-existing phenomenology such
as parkinsonism and myoclonus. Identification of
associated phenomenologies may have important
implications for treatment. For example, dystonia
associated with parkinsonism can be found in DYT3
dystonia (Lubag disease), DTY12 dystonia (rapid-on-
set dystonia parkinsonism, RDP), and NBIA.
In DYT11 dystonia (myoclonus-dystonia
syndrome), myoclonus may predominate, and
symptomatic control is sometimes achieved by
treating the myoclonus. Data is limited by a small
number of reported patients and limited number
of controlled trials. Given the subcortical origin
of the myoclonus, it is reasonable to use
clonazepam [42–46] or levetiracetam [46]. Data in
double-blind placebo-controlled trials is unavailable,
and in our experience levetiracetam has benefitted
some patients (unpublished data). A recent randomized
controlled trial in 23 patients demonstrated improve-
ment of myoclonus with zonisamide [47]. Other medi-
cations reported in small studies include sodium
oxybate [48, 49], tetrabenazine [50], anticholinergics
(which improved only dystonia but not myoclonic com-
ponent) [43], among others. Valproic acid was found to
be ineffective in several studies [43, 51]. In severe
medically refractory cases, pallidal (GPi) deep brain
stimulation (DBS) should be considered [52–56], earl-
ier rather than later [57, 58].
4) What treatment modality or modalities should be
initiated?
As a general rule, less invasive modalities such as
medications and/or BoNT are usually tried before DBS,
although the dramatic response of DYT1 generalized
dystonia or DYT11 dystonia to DBS supports early
intervention [52–61]. The list of indications for DBS in
dystonia has been expanding. Some examples are
DYT3 dystonia [62–66], cerebral palsy [67, 68],
pantothenate kinase-associated neurodegeneration
[69, 70] and idiopathic cervical dystonia [71].
The decision whether to use oral medication vs.
BoNT depends on the distribution of dystonia. For
example, BoNT is first-line therapy in cervical dystonia,
blepharospasm or spasmodic dysphonia, due to its
excellent efficacy and tolerability. BoNT is usually
employed first in focal or segmental dystonia
where a limited number of muscles can be tar-
geted. In generalized dystonia, BoNT may be of
use in focal areas in order to relieve discomfort
and improve function, such as injecting the hands in
dystonic cerebral palsy. However, oral medications are
almost always required.
We summarize the treatment modalities for each
form of dystonia in Table 3. Given the relative rarity
and heterogeneity of dystonia, there have been only
a handful of double blind randomized placebo
controlled (DBPC) studies, and much of the
evidence supporting these recommendations is level
4. Thus it is important to maintain flexibility in
individualizing treatment.
Medication selection and treatment strategy
General considerations
The strategy, developed by Fahn [5], is to “start low and
go slow”: medications should be started at a low dose,
and titrated up slowly to the lowest dose that is effective
for sufficient symptom control without side effects. The
rate of titration may depend on age: every 3–4 days in
children, compared to every 1 week in adults. If symp-
toms are still not adequately controlled or benefits are
not sustained, medications can be titrated up further.
Should side effects emerge, we may try holding the dose
constant until they disappear, but oftentimes reduction
of the dose is needed. If side effects are severe, intoler-
able or persist, the medications should be lowered.
A combination approach is used when monotherapy
achieves a “good” dose but symptom control is incomplete,
or dosage is impeded by side effects. Anticholinergics may
sometimes have a paradoxical effect i.e. worsening of dys-
tonia at low dose which will disappear at high dosage [5],
possibly due to pre-synaptic inhibition. In this circum-
stance, pushing the dose higher slowly may be considered,
with close monitoring for side effects. Peak effect or bene-
fits of some medications such as trihexyphenidyl may not
be evident until the dose is held constant for at least 2–4
weeks [72].
The dose ranges and titration schedule of the major
medications are summarized in Fig. 2. In the 1980s,
anticholinergics were used at high dosage [5, 6, 72]. How-
ever, in our current clinical practice, it is not very common
to have patients on trihexyphenidyl higher than 30–40 mg
daily, compared to up to 120 mg/day in the trials. Use of
anticholinergics at high dosage is limited by side effects.
For levodopa use in non-DRD dystonia, the dose and titra-
tion are similar to their use in mild Parkinson’s disease.
Which medications should be started first? Most clini-
cians in the U.S. use trihexyphenidyl as their first-line
agent (Table 1B). However there are no available head-
to-head comparisons with other agents in randomized
placebo controlled trials. Baclofen may have a more
important role in childhood dystonia with associated
spasticity, such as in cerebral palsy [73]. Nonetheless, we
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Table 3 Summary of selection of treatment modalities in dystonia
After excluding disorders with etiology-specific therapies as shown in Table 1, symptomatic therapy in this table is then considered. This table summarizes treatment
modalities in each dystonic disorder. Three major treatment modalities include medications, botulinum toxin injections and deep brain stimulation, among others. Of
note, since DRD is an important “don’t-miss” diagnosis, “levodopa trial” is also included here under “Medication”. Of note, levodopa in this case serves for diagnostic and
therapeutic purposes (“etiology-specific therapy”). In DYT5 or DRD, levodopa is the specific therapy which typically leads to dramatic and sustained benefit. If levodopa
is used for other purposes such as “symptomatic therapy” for dystonia or coexisting parkinsonism, it is shown under “Others”
“++” represents first-line modality or, for DBS, there is a low threshold to consider; “+” represents second-line or adjunctive modality when used as a combination ther-
apy; “+/−” means benefits remain unclear. “?+” means that levodopa trial in cervical dystonia is questionable: it may be considered but not as strongly indicated as in
limb-onset or generalized dystonia in adults
1LD trial in this case includes only for diagnostic and therapeutic purposes, particularly when DRD is suspected or cannot be excluded. LD as a symptomatic therapy is
shown under “Others”
2BoNT can be used to target focally at the most debilitating muscle group(s) e.g. to relieve discomfort or improve range of motion for rehabilitation or hygiene
3DBS has been reported. These disorders are expanding indications for DBS, and may require further studies to confirm benefits
4Especially the ones with limb-onset dystonia
5DBS in DYT6 dystonia is generally less beneficial than DYT1 dystonia, however it has still been performed
6Pallidal (GPi) stimulation relieves both dystonia and myoclonus
7LD in this case is used as a symptomatic therapy to treat coexisting parkinsonism
8Avoding triggers is helpful in paroxysmal dyskinesias such as avoiding caffeine, alcohol and sleep deprivation in PNKD, and avoiding strenuous exercise in PED
9Need to search for GLUT1 deficiency syndrome in PED. Ketogenic diet can be initiated once the diagnosis is confirmed
10Especially when there is involvement of complex muscle groups or tongue
11Adductor spasmodic dysphonia (ADSD) typically has better response to BoNT than abductor spasmodic dysphonia (ABSD)
12Not recommended in embouchure dystonia
13In order to rule out DRD, and also Parkinson’s disease presenting with foot or lower limb dystonia
Abbreviations: BoNT botulinum toxin injection, CBZ carbamazepine, CD cervical dystonia, CLZ clonazepam, CP cerebral palsy, DBS deep brain stimulation, GHB γ-hydroxybutyric
acid or sodium oxybate, GLUT1 glucose transporter type 1, GPi globus pallidus interna, iLCrD idiopathic lower cranial dystonia, ITB intrathecal baclofen, LD levodopa, LVT
levetiracetam, PED paroxysmal exercise-induced dystonia, PKD paroxysmal kinesigenic dyskinesia, PNKD paroxysmal non-kinesigenic dyskinesia, Rx, treatment, SD, spasmodic
dysphonia, Sym Rx symptomatic treatment, TSFD task-specific focal dystonia
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suggest initiation with trihexyphenidyl if control of dys-
tonia is a priority. If side effects occur or clinical benefits
are not achieved, switching to or adding baclofen may
be entertained. Clonazepam is generally considered a
second- or third-line agent.
Of note, paroxysmal dyskinesias are unique, and the
therapeutic approach is quite different from other
dystonias: antiepileptics and avoiding triggers are the
mainstay therapy. The first important step is to exclude
secondary paroxysmal dyskinesias (such as from demye-
linating diseases, parathyroid disorders and vascular
lesions including Moyamoya syndrome) [74–78] espe-
cially in atypical age group or adults, since specific
treatment of underlying disorders are indicated. Three
main types of primary paroxysmal dyskinesias include
paroxysmal kinesigenic dyskinesia (PKD), paroxysmal
nonkinesigenic dyskinesia (PNKD) and paroxysmal
exercise-induced dyskinesia (PED). The most common
mutations in PKD and PNKD are in the PRRT2 [79] and
PNKD (a.k.a. MR-1) [80, 81] genes, respectively. Some
PED patients carry mutations in the GLUT1 or SLC2A1
gene [82], and are considered to be in the phenotypic
spectrum of glucose transporter type 1 deficiency syn-
drome (Glut1 DS).
PKD patients often respond completely to low dose
carbamazepine (50–400 mg/day in adults or 1.5-15 mg/
kg/day in children) [83–85], or less commonly used
phenytoin (150–300 mg/day in adults or 5 mg/kg/day in
children) [85–87]. The dosage for PKD is typically lower
than that in epilepsy. FDA recommends the HLA-B*1502
in patients at high risk of Steven-Johnson syndrome or
toxic epidermal necrolysis such as those of Asian descent
prior to initiation of carbamazepine [88]. Other antiepilep-
tics such as oxcarbazepine [83, 89–92], levetiracetam [93],
gabapentin [94], topiramate [95], valproic acid [96] and
lamotrigine [97–99] have been reported. Acetazolamide
has been reported in secondary PKD due to demyelinating
diseases [100]. PNKD patients should avoid precipitating
factors such as caffeine, alcohol and sleep deprivation.
The response to anticonvulsants is less favorable in PNKD
compared to PKD [101, 102]. Clonazepam (2–4 mg/day)
may be used as first-line treatment [101, 103–105]. Other
medications such as acetazolamide [105], haloperidol
[106], gabapentin [104] and oxcarbazepine [107] have
been reported in PNKD. PED patients should avoid pro-
longed exercise, and PED patients with Glut1 DS can
benefit from the ketogenic diet [82, 108]. Management of
dystonic storm will not be discussed here.
The history of the medical treatment of dystonia offers
many valuable lessons. Serendipity has played an import-
ant role in the development of medical treatment. In the
following section, we will start the discussion of medica-
tions affecting each neurotransmitter with a historical
review.
Medications primarily affecting the cholinergic system
In 1952, beneficial effects of trihexyphenidyl in writer’s
cramp and “dystonia musculorum deformans” were first
reported [109, 110]. In 1983, Fahn conducted the first
open-label study of high dose anticholinergics in
dystonia using trihexyphenidyl and ethopropazine [5]. Anti-
cholinergics were employed in various forms of dystonia,
both “primary and secondary”, excluding tardive dystonia
and Meige syndrome. Benefits were found in 61% of the
children and 38% of the adults, with average trihexyphenidyl
doses of 41 and 24 mg respectively. In 1986, a prospective
DBPC crossover trial of anticholinergics in children and
young adults employed doses up to 120 mg/day of trihexy-
phenidyl [72]. A clinically significant response was seen in
71% of a total of 31 patients, and benefit remained in 42% of
the patients after 2.4 years of follow up. More benefit was
demonstrated in children, possibly due to better tolerability,
and in patients who received treatment earlier, within 5 years
of disease onset [5, 6, 72].
Anticholinergics have been shown to benefit various
forms of dystonia including focal [111], cranial dystonia
[112], and secondary dystonia including dystonia in cere-
bral palsy [72, 113–115], after ischemic stroke [116] and
in tardive dystonia [114, 117].
The adverse effects of anticholinergics encompass central
and autonomic symptoms (Fig. 2). Central side effects in-
clude sedation, cognitive slowing, confusion, memory im-
pairment, psychosis and chorea. Autonomic side effects
include blurred vision due to mydriasis, dry mouth, urinary
retention and constipation. Anticholinergics are contraindi-
cated in patients with a history of acute angle-closure
glaucoma. Certain autonomic side effects may be relieved by
using pilocarpine eye drop (for blurred vision), or pyridostig-
mine for other symptoms. Abrupt discontinuation of anti-
cholinergics has been reported to rarely worsen dystonia
and can even trigger life-threatening cholinergic crisis [118].
In clinical practice, the issue of anticholinergic withdrawal
does not appear to be as concerning compared to baclofen
or benzodiazepines. Nonetheless, we recommend tapering
anticholinergics very slowly.
Medications primarily affecting the GABAergic system
There have been no DBPC trials of baclofen or benzodi-
azepine in dystonia. Baclofen was used in spasticity before
it was applied to dystonia. In 1982, Brennan reported im-
provement of Meige syndrome with a combination of so-
dium valproate and baclofen [119]. Afterwards baclofen
was reported to be useful in tardive dystonia [120]. Greene
published a retrospective open label trial in 1988 [6].
Twenty percent of 108 patients had benefits from baclo-
fen. The dose ranged from 25 to 120 mg/day (mean
82 mg/day). There was a trend of more benefit in
blepharospasm compared to other forms of dystonia.
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Later, Greene and Fahn also reported beneficial effects of
baclofen in seven of 16 patients with idiopathic childhood
dystonia [121]. Some who responded to baclofen did not
have a good or sustained response to anticholinergics. In
line with the previous study [6], a better response to
baclofen correlated with shorter duration of therapy, espe-
cially when initiated within 3 years of symptom onset.
Due to limited cerebrospinal fluid penetration [122],
intrathecal baclofen (ITB) was tried, initially for
spasticity [123, 124], and later in dystonia [125–131].
Efficacy of ITB was initially reported in intractable axial
dystonia by Narayan in 1991 [129], and subsequently in
dystonic cerebral palsy with lower extremity involvement
[130, 131]. The benefits to the lower limbs [132] may be
Fig. 2 Diagram of major medications for symptomatic therapy in dystonia classified by their neurotransmitter systems. The corresponding bars show
starting doses, titration doses (amount to increase with each titration period), usual therapeutic doses, our recommended maximum doses in clincial
practice and ceiling doses. Of note, the bars do not represent the acutal scales. The table summarizes dosage forms, dosing, side effects, caution and
Food and Drug Administration (FDA) pregnancy category of each medication. Levodopa is not included here as its major role in dystonia is for
etiology-specific therapy as mentioned in Table 2 and the text. Abbreviations: mg, milligram; TID, three times a day; BID, two times a day
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associated with the gravity-induced concentration
gradient in the thecal sac [133]. Albright reported intra-
ventricular baclofen (IVB) use in two patients with dys-
tonic cerebral palsy, one of whom previously failed ITB
therapy and the other with a complex spinal anatomy
precluding the intrathecal procedure [134]. Benefits of
IVB in other secondary dystonias such as glutaric
aciduria type 1 have been reported [135]. IVB is a useful
alternative in patients with refractory dystonia requiring
multiple revisions of ITB pump [136]. Before pump
placement, patients generally receive a trial dose of ITB
in order to assess their expected response. ITB has be-
come less popular in dystonia due to the complication
rates from the surgical procedures and hardware-related
problems including infection or pump malfunction. In
addition, abrupt discontinuation of ITB can lead to dys-
tonic storm or baclofen withdrawal syndrome, which
may be life-threatening.
Baclofen is generally considered as a second-line
agent. Side effects include drowsiness, dizziness, fatigue
and nausea. Its use in dystonia with coexisting spasticity
may lead to excessively reduced muscle tone. It is critical
to gradually taper the dose down and not to abruptly
discontinue ITB in order to prevent the baclofen with-
drawal syndrome.
With regard to benzodiazepines, diazepam therapy was re-
ported in “dystonia musculorum deformans progressiva”
and spasmodic torticollis [137–139]. In 1988, Greene found
benefit of clonazepam in 16% of 115 patients with various
forms of dystonia, including secondary dystonia [6]. In one
study of 33 patients with acquired hemidystonia, clonaze-
pam and diazepam were found to be the most effective
drugs, although others reported more benefit with anticho-
linergics [140]. No head-to-head comparisons between vari-
ous benzodiazepines are available.
In general, benzodiazepines are considered to be a
second- or third-line agent. Clonazepam and diazepam
are the two most commonly used drugs, partly due to
their relatively long half-lives. Side effects of benzodiaz-
epines include sedation, depression, nocturnal drooling
and behavioral disinhibition. As with baclofen, abrupt
discontinuation can lead to a withdrawal syndrome and
seizures. Tachyphylaxis has been reported in other indi-
cations [141], although to our knowledge not in
dystonia.
Medications primarily affecting the dopaminergic system
Levodopa therapy entered the field of dystonia in 1976
when Segawa first reported a dramatic response to low
dose levodopa in two female cousins with “hereditary pro-
gressive dystonia with marked diurnal fluctuations” [21],
subsequently named Segawa syndrome or DRD. Indeed,
Beck originally described in 1957 an 8.5-year-old girl with
“dystonia musculorum deformans” [142] who was noted
to have diurnal fluctuations later by Corner [110]. The
gene discoveries were already discussed above.
Levodopa can serve two different purposes in dystonia
therapy: 1) as an etiology-specific treatment in DRD, and
2) as a symptomatic therapy in other forms of dystonia
where the dramatic response to levodopa is unfortu-
nately not replicated. It may also be used to treat parkin-
sonism that coexists with dystonia such as in RDP [143].
In our practice, we rarely use levodopa or dopamine ag-
onists to treat dystonia symptomatically. Side effects of
levodopa include nausea, orthostatic hypotension and
psychosis. However in DRD it is typically administered
at low doses, so side effects are less frequent. Levodopa-
induced dyskinesias are uncommon in DRD.
In 1972, Swash reported only slight benefit of TBZ in
spasmodic torticollis [144]. In 1982, a double blind
crossover trial by Jankovic demonstrated improvement
in 11 of 12 patients [145]. TBZ has been used in various
forms of dystonia and other hyperkinetic movement dis-
orders [145–149], however benefits are greater in tardive
dystonia compared to other forms [147]. TBZ was not
available in the U.S. until FDA approval in 2008 for cho-
rea associated with Huntington’s disease, and it has been
used off-label in a variety of hyperkinetic movement dis-
orders including dystonia [150].
TBZ is rarely used as a first-line agent, except in tardive
dystonia [150]. Reserpine is rarely used for dystonia due to
its peripheral side effects (e.g. hypotension). Clinical use of
metyrosine [151] is restricted by its availability. The most
important adverse effects of TBZ are parkinsonism and
depression. The FDA label recommends CYP2D6 geno-
typing when using TBZ above 50 mg/day [152]. Patients
with exceptionally high activity of CYP2D6 enzyme, called
ultrarapid metabolizers, can theoretically have short
pharmacological effects. One study found that ultrarapid
metabolizers needed longer titration and tended to require
higher dosages [153].
Deutetrabenazine (SD-809) is a new medication that is
structurally related to TBZ and thus has similar action
as a VMAT2 inhibitor. The added deuterium molecule
attenuates CYP2D6 activity, thereby prolonging its half-
life. A trial is underway for chorea in Huntington’s
disease [154], and it is likely that the indications may ex-
pand to tardive dyskinesias and dystonia in the future.
While DRBAs can cause acute dystonic reactions and
tardive dystonia, the paradox is that they can sometimes im-
prove dystonia. Conflicting data revealed benefits in some
studies, particularly in tardive dystonia [146, 155–157], but
not in others [158, 159]. The use of the DRBAs as routine
treatment for dystonia is generally discouraged due to the
risk of engendering tardive syndromes [7, 160–162]. DRBAs
acting at D2 receptors carry higher risks compared to the
ones acting at others, including D4. Clozapine is considered
to be a “true” atypical neuroleptic: it blocks the D4 receptor
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without blocking D2, and tardive syndromes have not been
reported with clozapine. Quetiapine has been rarely re-
ported to cause tardive dyskinesia, nevertheless in clinical
practice it is used more frequently since clozapine requires
frequent blood draws to monitor for agranulocystosis.
In our clinical practice, we generally preserve dopa-
mine reducing agents for tardive syndromes or for pa-
tients with generalized dystonia who have not obtained
adequate benefit from other medications. We choose
TBZ first. If it is ineffective or intolerable side effects en-
sue, our next preferred treatment is clozapine.
Other agents
A variety of medications from small trials or case reports
include other muscle relaxants such as carisoprodol or
tizanidine, anticonvulsants such as sodium valproate,
carbamazepine and phenytoin, as well as L-tryptophan
and riluzole. Some medications, such as mexilitine and
5-hydroxytryptophan, have largely disappeared from
current clinical practice. We will discuss three selected
medications which have been reported to have large
clinical benefits in small numbers of patients: sodium
oxybate (or sodium γ-hydroxybutyrate [GHB]; Xyrem®),
zolpidem, and cannabinoids.
Sodium oxybate, a GABA derivative, acts as a GABAB
and GHB receptor agonist. It was approved in the U.S. for
treatment of cataplexy in narcolepsy in 2002. Its biological
effects similar to ethanol render applications in several
alcohol-responsive movement disorders including essen-
tial tremor, myoclonus-dystonia syndrome, spasmodic
dysphonia (SD), as well as posthypoxic myoclonus [48, 49,
163–165]. Frucht reported beneficial effects treating three
patients with myoclonus-dystonia syndrome who were al-
cohol responsive [49]. However alcohol abuse and de-
pendence are not uncommon in DYT11 patients [166],
and the drug may not be safe in this population. Alcohol
responsiveness has been reported in about 55-60% of pa-
tients with SD [167]. In one case report [164] as well as
ongoing experience in our center (unpublished data), so-
dium oxybate has beneficial effects in SD patients who are
alcohol-responsive. Interestingly, one patient had a pro-
longed effect for several months after a single dose of so-
dium oxybate [164]. Off-label use of sodium oxybate in
clinical practice may be challenging due to limitation in
insurance coverage and strict substance control.
Zolpidem was initially claimed as a non-addicitive non-
benzodiazepine hypnotic drug. Unfortunately, addictive
potential has been reported with zolpidem [168]. The very
first reports of zolpidem use in movement disorders were
in patients with Parkinson’s disease and progressive supra-
nuclear palsy [169, 170]. Evidente reported benefits in
three patients with DTY3 dystonia [171]. Later reports of
zolpidem in different forms of dystonia included focal,
segmental and generalized dystonia [172–176]. Miyazaki
found 28, 18 and 31% improvement in generalized, Meige
syndrome/blepharospasm and hand dystonia, respectively
[172]. The dose ranged from 5 to 20 mg/day with an aver-
age dose of 8–12 mg/day. The main side effect that limits
dose is sedation.
Medical cannabinoids have become a popular topic
since some states in the U.S. have legally approved canna-
bis use [177, 178]. Cannabinoids refer to a group of medi-
cations that act at the cannabinoid receptors, CB1 and/or
CB2. CB1 receptors are primarily present in the brain,
particularly in basal ganglia, limbic system, cerebellum
and cerebral cortex. CB2 are mainly found in the spleen,
tonsils, bone marrow and peripheral leukocytes. CB1 re-
ceptors are located at the presynaptic glutamatergic and
GABAergic terminal axons innervating the striatal MSNs,
as well as at the MSNs’ terminal axons [179, 180]. Activa-
tion of CB1 receptor leads to gluatamate release.
Cannabinoids can be derived from plants (phytocan-
nabinoids e.g. delta-9-tetrahydrocannobinoid [THC],
cannabinol and cannabidiol), synthesized (synthetic
cannabinoids e.g. nabilone) or produced within the hu-
man body (endocannabinoids). Dronabinol (Marinol®)
is a synthetic THC. THC has psychoactive effects such
as euphoria, whereas cannabidiol has more sedative an-
tiemetic and analgesic effects.
Several studies showed mixed results of cannabinoids
in various forms of dystonia [181, 182]. Some showed
benefit [183–185], whereas two small randomized DBPC
trials did not [186, 187]. Benefits of cannabinoids in dys-
tonia were concluded as “unknown efficacy”, according
to an American Academy of Neurology (AAN) system-
atic review [178]. Anecdotally, benefit of THC has also
demonstrated in one case of musicians’ hand dystonia
(Altenmüller, personal communication). Further clinical
experience and studies are required.
The evolving role of medical treatment in dystonia:
uncertainty for clinicians
With advances in diagnosis and treatment, therapeutic
strategies including pharmacological management in dys-
tonia have evolved. Progresses in other areas such as
BoNT, neuromodulation and disease-specific treatment
have changed the way patients are treated. Medical treat-
ment in dystonia now is quite different from two decades
ago. The following practical questions may help guide the
clinician embarking on medical treatment of dystonia.
Q: Should patients with all forms of dystonia be treated
the same way?
A: No. Etiology-specific approach should be contem-
plated first if there are known treatable etiologies
(Table 2). In DRD, levodopa use is diagnostic
and may produce dramatic response. In combined
dystonia, co-existing phenomenology such as
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parkinsonism in DYT12 dystonia or myoclonus in
DYT11 dystonia should be taken into consideration.
In idiopathic isolated or primary dystonia where
etiology-specific approaches are unavailable, symp-
tomatic treatment is the norm. A suggested thera-
peutic scheme appears in Table 3.
Q: Does the distribution of dystonia affect choice of
therapy and response?
A: BoNT is preferred in focal or segmental dystonia,
whereas medical therapy is a first choice for gen-
eralized dystonia. In focal/segmental dystonia,
medical treatment may have a primary role when
BoNT is not technically feasible, or where BoNT
is prone to side effects or functional impairment
such as tongue or embouchure dystonia [188].
In general, location of dystonia does not impact
the choice of medication. As discussed, we start
with an anticholinergic as a first-line, and baclo-
fen or clonazepam as a second-line agent. Some
experts may prefer one medication to another in
some forms of dystonia based on clinical experi-
ence, for example benzodiazepines in hemidysto-
nia [140].
Q: Do adults and children respond the same way to
treatment?
A: Probably not, although evidence is lacking. Children
tolerate higher doses of medications than adults.
Q: Should every patient have a witnessed trial of
levodopa?
A: Not necessarily. The rule of thumb is if DRD cannot
be ruled out, a levodopa trial is essential. Generally,
we recommend a levodopa trial in all children or
adults with generalized or focal limb dystonia, since
this could represent an atypical phenotype of DRD.
If patients already have a clear alternative diagnosis,
a levodopa trial is not necessary.
Q: How should medications be used in the modern era
of BoNT? During what period: prior, concurrent or
when BoNT wears off?
A: As seen in Table 3, in some forms of focal dystonia
such as blepharospasm, SD or cervical dystonia,
BoNT is typically used first.
Q: How should medications be used in the modern era
of surgery?
A: Typically almost all patients undergo medication trials
at some point prior to the decision to undergo DBS
surgery. There is a modern trend to pursue surgery
earlier in the disease course. This is particularly
applicable to disorders such as DYT1 generalized
dystonia or DYT11 dystonia.
After DBS surgery, medications are usually left un-
changed until the initial programming. On the day of
the initial programming, we ask the patient to hold
one or two doses of the medication(s). Once benefits
from DBS are seen (which may take months in DYT1
dystonia), we then taper down the medication(s)
slowly.
Conclusion
Dystonia remains a challenging field in both diagnostic
and therapeutic aspects. Further understanding of its
pathophysiology may shed light on more specific thera-
pies. Symptomatic medical therapy can improve quality
of life and should not be overlooked.
Video Legends:
Video segment 1: Video segment 1 demonstrates
examples of dystonia mimics and psychogenic dystonia.
Patient 1 was referred for evaluation of head tilt,
concerning for “cervical dystonia”. However, on
examination the left head tilt was relatively fixed even
when she turned her head in different directions. Palpation
revealed a harder-than-normal consistency of her left
sternocleidomastoid muscle due to fibrosis. She was
referrred for surgical evaluation after our diagnosis of
congenital muscular torticollis. Patient 2 had a history of
previous trauma to the left foot several months prior.
Examination demonstrated relatively fixed inversion
of the left foot when sitting and walking, and no
improvement when walking backwards. She was
diagnosed with complex regional pain syndrome.
Patient 3 presented with difficulty moving the left
leg. Examination revealed a slight increase in tone of
the left leg to passive range of motion, as well as a
slightly brisker quadriceps reflex on the left. His left
leg was slightly more clumsy than the right with
active range of motion and when walking. The
diagnosis of stiff limb syndrome, a variant of stiff
person syndrome, was confirmed by marked elevation
(>250 U/ml) of anti-glutamic acid decarboxylase
(anti-GAD) antibody. The next videos demonstrate
a variety of psychogenic dystonias including psycho-
genic jaw dystonia presenting with left jaw deviation
(Patient 4), psychogenic laryngeal dystonia with
choking-like symptom (Patient 5), psychogenic upper
and lower limb dystonia (Patient 6), psychogenic left
foot dystonia (Patient 7), and psychogenic right hand
dystonia (Patient 8).
Video segment 2: Video segment 2 demonstrates
select examples of “don’t-miss” diagnoses. Patient 1
is a teenage girl with Wilson’s disease. She had
prominent lower facial dystonia, a risus sardonicus,
Termsarasab et al. Journal of Clinical Movement Disorders  (2016) 3:19 Page 12 of 18
and a jerky 6-Hz tremor of the left fingers. Patient 2
also has a diagnosis of Wilson’s disease. She
presented with cervical dystonia, left shift, slight head
tilting to the right (with her chin pointing to the left)
and prominent right shoulder elevation. Lateral
rotation of her neck to the right was more difficult
than to the left. A low amplitude dystonic jerky head
tremor was intermittently seen. Her parkinsonian
features including facial masking and bradykinesia on
finger tapping were mild. A classic Kayser-Fleischer
ring was demonstrated as a relatively thick brown rim
along the entire circumference of the limbus. Both
Patients 1 and 2 experienced marked benefit from
oral copper chelating therapy. Patient 3 is a 10-year-
old girl with a genetically confirmed mutation in the
ATP1A3 gene. She presented with an intermediate
phenotype between alternating hemiplegia of child-
hood and rapid-onset dystonia parkinsonism [143].
The home video demonstrated an episode of upward
oculogyria with slight head tilting to the left, during
which her consciousness remained intact. Oculogyric
episodes disappeared when she was treated with levo-
dopa 300 mg/day, but moderate residual dystonic pos-
turing of the left hand was still present.
Video segment 3: Video segment 3 demonstrates
example of patients with primary dystonia. The first
three patients have childhood-onset genetically
confirmed DYT1 dystonia with predominant foot or leg
involvement. Patient 1 was unable to stand or walk in-
dependently due to bilateral foot dystonia. With 15 mg/
day of trihexyphenidyl and 30 mg/day of baclofen, she
was able to stand and take a few steps with minimal
support. Patient 2 demonstrated flexion dystonia of her
left more than right foot that was moderately improved
with trihexyphenidyl 45 mg/day and baclofen 30 mg/
day. Patient 3 demonstrated prominent inversion of the
left foot, with much milder right foot dystonia. His dys-
tonia was more prominent with activation such as during
the swing phase of walking. With trihexyphenidyl
10 mg/day, the left foot dystonia improved only slighlty,
and the residual right foot dystonia was minimal. Patient
4 is a girl who presented with dystonia, negative for
DYT1 and DYT6 mutations. Her dystonia involved the
trunk and, to a lesser degree, all extremities. Prominent
truncal twisting was demonstrated even when she was
sitting in the chair. This improved with trihexyphenidyl
30 mg/day, but she still had residual truncal dystonia seen
as pelvic tilting when walking. She ultimately underwent
bilateral GPi DBS surgery with marked improvement in
her dystonia.
Video segment 4: Video segment 4 demonstrates dopa-
responsive dystonia (DRD; Patients 1–2), one of the most
crucial “don’t-miss” diagnoses in dystonia, and paroxysmal
kinesigenic dyskinesia (Patients 3–5). These two disorders
are treated with, in respective order, low dose levodopa and
low dose carbamazepine with dramatic benefits. Patient 1
had residual minimal dystonia of her feet after she was
given a low dose levodopa. Patient 2, her mother, un-
fortunately underwent the orthopedic surgical correc-
tions of her deformities in childhood due to a missed
diagnosis. Recognition of DRD and a levodopa trial
would have prevented her from these unnecessary in-
vasive procedure. Patient 3 had an episode of paroxysmal
dystonia involving mainly his trunk (extension and
flexion) lasting a few seconds while standing. The
second home video displayed another episode of
dystonia involving both hands and arms while he
was sitting. He returned to his normal state after each
episode. Patient 4 presented with episodes of truncal
dystonia. The one captured in this home video
demonstrated truncal twisting while standing. He
held the chair during the episode which lasted several
seconds before returning to his normal baseline.
Home videos of Patient 5 demonstrate episodes of
dystonia primarily involving both legs and feet. Each
episode lasted a few seconds. The first one occurred
while he was sitting in the bed. During the second
episode, he deliberately made a step with his right
foot due to paroxysmal dystonia.
Video segment 5: Video segment 5 demonstrates a
variety of focal dystonias. The first two patients have
velopharyngeal dystonia, a form of focal task-specific dys-
tonia involving pharyngeal muscles and soft palate (velo-
pharynx) which leads to inabilty to close the air passage
connecting the mouth and nasal cavity, producing a nasal
quality of speech. Patient 1 is a 41-year-old woman who
presented with breathy and hypernasal voice. Stroboscopic
examination of her larynx did not reveal evidence of spas-
modic dysphonia. She was started on trihexyphenidyl
which was titrated up to 12 mg/day, and on follow-up visit
two months later her speech improved by approximately
75%. Patient 2 is a 61-year-old man who presented with
two years of nasal speech. Marked improvement with tri-
hexyphenidyl 12 mg/day was seen. Patients 3 and 4 dem-
onstrate a variety of idiopathic lower cranial dystonias
(iLCrD). Further details about this particular topic can be
found in Ref [189]. Patient 3 demonstrates pure left jaw
deviation aggravated by speaking, improved with trihexy-
phenidyl 2 mg/day. Patient 4 is a woman with severe jaw
opening dystonia triggered by speaking. Light touching of
her chin served as a geste antagoniste that improved her
dystonia. She tried multiple medications including
trihexyphenidyl, baclofen, clonazepam and leveteiracetam
without success due to side effects before achieving
an adequate response with diazepam 15 mg/day.
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Video segment 6: Video segment 6 demonstrates a
woman with left hemidystonia. She placed her left hand
underneatth her left leg in order to compensate. When
walking, dystonia of the left arm, seen as flexion of the
left elbow, extension of the left wrist and flexion of her
fingers was demonstrated. The left arm braced her trunk
while walking with marked reduction in arm swing. On
follow up visit several years later, on lorazepam 2 mg/
day, she had moderate dystonic posturing of the left
hand at rest and when holding her arms in outstretched
position. Mild dystonic posturing of the left foot was
also demonstrated when sitting. Dystonic posturing of
the left arm was less prominent compared to the
previous examination.
Video segment 7: Video segment 7 demonstrates a
variety of tardive dystonias. Both patients had a history of
dopamine receptor blocking agent use in the past. Patient 1
had phasic cervical dystonia, characterized by intermittent
jerky anterior neck shifting in commbination with neck
flexion. Dystonia of the forehead muscles included
frontalis and procerus involvement. The dystonia was
alleviated by lightly touching her face with her hand.
Patient 2 demonstrated intermittent truncal flexion when
sitting and walking. He underwent bilateral pallidal DBS
surgery with resolution of his truncal dystonia.
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